| NCT07154290 | A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | NOT_YET_RECRUITING | PHASE2 | 2026-01-26 | 2030-05-17 | 2030-05-17 |
| NCT07112378 | A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis | RECRUITING | PHASE3 | 2026-01-13 | 2028-12-11 | 2028-08-21 |
| NCT07213778 | REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants | NOT_YET_RECRUITING | PHASE3 | 2025-12-05 | 2027-07-16 | 2027-07-16 |
| NCT07187089 | Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab | NOT_YET_RECRUITING | PHASE4 | 2025-11-11 | 2028-01-05 | 2027-12-23 |
| NCT06975787 | Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis | NOT_YET_RECRUITING | PHASE1 | 2025-11-06 | 2028-07-13 | 2028-07-13 |
| NCT07154745 | A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently | NOT_YET_RECRUITING | PHASE3 | 2025-10-25 | 2031-01-25 | 2031-01-25 |
| NCT07175428 | Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | NOT_YET_RECRUITING | PHASE2 | 2025-10-21 | 2027-04-26 | 2027-04-26 |
| NCT07187401 | A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor | NOT_YET_RECRUITING | PHASE1, PHASE2 | 2025-10-13 | 2029-12-07 | 2029-09-14 |
| NCT07142343 | A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease | NOT_YET_RECRUITING | PHASE4 | 2025-10-09 | 2029-08-24 | 2029-08-24 |
| NCT07015905 | REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults | RECRUITING | PHASE3 | 2025-06-25 | 2027-05-12 | 2027-02-20 |
| NCT06970405 | Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women | WITHDRAWN | PHASE1 | 2025-05-29 | 2026-06-08 | 2026-06-08 |
| NCT06787612 | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer | RECRUITING | PHASE2 | 2025-05-28 | 2028-12-07 | 2028-12-07 |
| NCT06608901 | A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension | RECRUITING | PHASE2 | 2025-05-05 | 2026-10-19 | 2026-07-23 |
| NCT06836609 | A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) | RECRUITING | PHASE1 | 2025-04-28 | 2027-03-01 | 2027-03-01 |
| NCT06833190 | REGN5381 in Adult Participants With Uncontrolled Hypertension | ACTIVE_NOT_RECRUITING | PHASE2 | 2025-04-16 | 2026-02-16 | 2025-12-01 |
| NCT06848088 | A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment | ENROLLING_BY_INVITATION | PHASE2 | 2025-04-14 | 2029-10-10 | 2029-10-10 |
| NCT06769698 | A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | PHASE2 | 2025-03-26 | 2029-11-28 | 2027-04-22 |
| NCT06669234 | Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults | RECRUITING | PHASE1 | 2025-03-06 | 2026-07-30 | 2026-07-30 |
| NCT06665828 | Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults | RECRUITING | PHASE1 | 2025-03-04 | 2025-12-12 | 2025-12-12 |
| NCT06784349 | ALN-APOC3 in Adult Participants With Dyslipidemia | RECRUITING | PHASE1, PHASE2 | 2025-01-27 | 2027-07-05 | 2027-07-05 |
| NCT06585410 | Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | RECRUITING | PHASE3 | 2025-01-02 | 2030-05-03 | 2030-05-03 |
| NCT06548100 | A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-12-16 | 2026-11-03 | 2026-07-14 |
| NCT06669247 | A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma | RECRUITING | PHASE1, PHASE2 | 2024-12-11 | 2035-11-01 | 2033-11-11 |
| NCT06602739 | A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy | COMPLETED | PHASE3 | 2024-11-19 | 2025-08-02 | 2025-04-23 |
| NCT06465329 | A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | PHASE2 | 2024-11-18 | 2030-05-02 | 2027-05-20 |
| NCT06384820 | Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) | WITHDRAWN | PHASE2 | 2024-11-14 | 2030-05-06 | 2026-06-08 |
| NCT06593600 | Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS) | RECRUITING | PHASE2 | 2024-11-13 | 2026-04-21 | 2026-01-28 |
| NCT06602726 | A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy | COMPLETED | PHASE3 | 2024-11-06 | 2025-08-02 | 2025-05-10 |
| NCT06541704 | A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy | RECRUITING | PHASE3 | 2024-10-30 | 2032-05-21 | 2027-11-29 |
| NCT06421636 | A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body | RECRUITING | PHASE2 | 2024-09-30 | 2028-01-24 | 2028-01-24 |
| NCT06444178 | Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants | COMPLETED | PHASE1 | 2024-09-30 | 2025-07-09 | 2025-04-07 |
| NCT06413680 | A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies | RECRUITING | PHASE1, PHASE2 | 2024-09-23 | 2030-02-03 | 2030-02-03 |
| NCT06299111 | A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) | RECRUITING | PHASE2 | 2024-09-20 | 2026-06-08 | 2026-06-08 |
| NCT06190951 | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma | RECRUITING | PHASE2 | 2024-09-18 | 2031-04-23 | 2027-03-11 |
| NCT06140524 | A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma | RECRUITING | PHASE2 | 2024-09-16 | 2032-05-18 | 2032-05-18 |
| NCT06379789 | A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B | RECRUITING | PHASE1, PHASE2 | 2024-09-11 | 2032-12-17 | 2032-12-17 |
| NCT06246916 | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | RECRUITING | PHASE3 | 2024-09-09 | 2033-07-10 | 2027-03-22 |
| NCT06351592 | First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) | RECRUITING | PHASE1 | 2024-08-28 | 2029-04-26 | 2029-04-26 |
| NCT06572228 | Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | RECRUITING | PHASE4 | 2024-08-26 | 2026-12-31 | 2026-12-31 |
| NCT06292780 | A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) | RECRUITING | PHASE1, PHASE2 | 2024-08-07 | 2035-02-20 | 2028-08-20 |
| NCT06469281 | A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers | RECRUITING | PHASE1 | 2024-08-06 | 2030-05-27 | 2030-05-27 |
| NCT06491914 | A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-07-24 | 2027-01-07 | 2025-08-21 |
| NCT06161441 | A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery | RECRUITING | PHASE2 | 2024-07-16 | 2029-04-19 | 2025-09-28 |
| NCT06452771 | A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults | ACTIVE_NOT_RECRUITING | PHASE1 | 2024-06-27 | 2025-09-30 | 2025-09-30 |
| NCT06454630 | A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants | COMPLETED | PHASE2 | 2024-06-27 | 2025-01-21 | 2025-01-21 |
| NCT06024408 | A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor | COMPLETED | PHASE1 | 2024-05-21 | 2025-07-07 | 2025-07-07 |
| NCT06369467 | Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy | RECRUITING | PHASE1 | 2024-05-17 | 2028-03-28 | 2028-03-28 |
| NCT05989126 | Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) | COMPLETED | PHASE3 | 2024-04-15 | 2024-05-31 | 2024-05-31 |
| NCT06237309 | REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-04-11 | 2025-12-30 | 2025-09-17 |
| NCT06299098 | A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-03-13 | 2026-11-04 | 2026-05-13 |
| NCT06230224 | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma | RECRUITING | PHASE3 | 2024-02-15 | 2027-05-14 | 2027-05-14 |
| NCT05955508 | A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma | RECRUITING | PHASE2 | 2024-01-30 | 2032-12-19 | 2032-12-19 |
| NCT06149286 | A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma | RECRUITING | PHASE3 | 2023-12-28 | 2029-01-23 | 2029-01-23 |
| NCT05828511 | A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment | RECRUITING | PHASE1, PHASE2 | 2023-12-19 | 2035-11-02 | 2035-11-02 |
| NCT06091865 | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-12-13 | 2029-04-30 | 2028-03-30 |
| NCT06091254 | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Follicular Lymphoma | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-12-12 | 2031-11-06 | 2028-02-19 |
| NCT06137482 | A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants | COMPLETED | PHASE1 | 2023-12-06 | 2025-02-11 | 2025-02-11 |
| NCT05923424 | A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults | COMPLETED | PHASE1 | 2023-11-28 | 2025-03-04 | 2025-03-04 |
| NCT06097364 | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-11-14 | 2029-07-29 | 2029-07-29 |
| NCT05730036 | A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma | RECRUITING | PHASE3 | 2023-09-18 | 2033-04-19 | 2033-04-19 |
| NCT05800015 | A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer | RECRUITING | PHASE2, PHASE3 | 2023-08-08 | 2031-12-23 | 2030-01-16 |
| NCT05970718 | A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants | COMPLETED | PHASE1 | 2023-08-07 | 2024-07-22 | 2024-07-22 |
| NCT05785767 | A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | PHASE2, PHASE3 | 2023-06-30 | 2032-02-05 | 2030-03-11 |
| NCT05788536 | A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations | RECRUITING | PHASE1, PHASE2 | 2023-06-27 | 2031-04-19 | 2031-04-19 |
| NCT05618808 | A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants | COMPLETED | PHASE2 | 2023-05-24 | 2024-05-27 | 2024-05-27 |
| NCT05831176 | A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-05-03 | 2026-11-25 | 2026-02-18 |
| NCT05557591 | A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-04-21 | 2028-05-16 | 2028-01-26 |
| NCT05685173 | A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas | RECRUITING | PHASE1 | 2023-04-12 | 2029-05-16 | 2027-06-02 |
| NCT05744921 | A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works | RECRUITING | PHASE3 | 2023-03-07 | 2029-02-26 | 2029-02-26 |
| NCT05519475 | A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition | RECRUITING | PHASE2 | 2023-02-09 | 2027-09-08 | 2027-09-08 |
| NCT05259709 | A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab | RECRUITING | PHASE1 | 2023-02-07 | 2027-01-06 | 2027-01-06 |
| NCT05608291 | A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-01-16 | 2030-02-15 | 2028-05-16 |
| NCT05603195 | A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants | COMPLETED | PHASE1 | 2023-01-12 | 2024-09-17 | 2024-09-17 |
| NCT05590585 | Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial | COMPLETED | PHASE4 | 2023-01-11 | 2024-11-14 | 2024-11-14 |
| NCT05546957 | Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants | COMPLETED | NA | 2023-01-05 | 2023-04-06 | 2023-04-06 |
| NCT05648214 | A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Non-Alcoholic Fatty Liver Disease (NAFLD) | ACTIVE_NOT_RECRUITING | PHASE1 | 2022-12-27 | 2025-10-18 | 2025-10-18 |
| NCT05394116 | A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-11-21 | 2029-02-27 | 2025-07-17 |
| NCT05481333 | A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants | COMPLETED | PHASE1 | 2022-10-24 | 2023-08-29 | 2023-08-29 |
| NCT05131204 | Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria | TERMINATED | PHASE3 | 2022-10-06 | 2023-07-12 | 2023-07-12 |
| NCT05505448 | A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants | COMPLETED | PHASE1 | 2022-09-15 | 2023-05-30 | 2023-05-30 |
| NCT05137054 | A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments | RECRUITING | PHASE1 | 2022-08-17 | 2034-09-26 | 2028-04-11 |
| NCT05430919 | Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants | COMPLETED | PHASE2 | 2022-08-15 | 2023-07-31 | 2023-07-31 |
| NCT05092347 | A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA) | RECRUITING | PHASE1, PHASE2 | 2022-08-02 | 2026-12-12 | 2026-01-17 |
| NCT05133531 | A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment | RECRUITING | PHASE3 | 2022-08-01 | 2027-01-28 | 2027-01-28 |
| NCT05352672 | Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma | RECRUITING | PHASE3 | 2022-07-14 | 2031-06-30 | 2025-06-30 |
| NCT05353166 | REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure | COMPLETED | PHASE2 | 2022-06-30 | 2025-06-02 | 2025-06-02 |
| NCT05291546 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants | COMPLETED | PHASE1 | 2022-04-13 | 2024-04-02 | 2024-04-02 |
| NCT05293678 | Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19 | COMPLETED | PHASE1 | 2022-04-12 | 2023-01-26 | 2023-01-26 |
| NCT05088460 | A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) | TERMINATED | PHASE2 | 2022-02-28 | 2024-04-18 | 2023-12-13 |
| NCT05169489 | A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2022-01-24 | 2025-08-31 | 2025-08-31 |
| NCT05181683 | COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers | COMPLETED | PHASE1 | 2022-01-07 | 2022-06-03 | 2022-06-03 |
| NCT05092581 | COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19 | TERMINATED | PHASE1 | 2021-12-16 | 2022-06-09 | 2022-06-09 |
| NCT05070858 | A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-12-14 | 2028-11-11 | 2025-07-18 |
| NCT05423327 | Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH) | TERMINATED | NA | 2021-12-09 | 2022-10-27 | 2022-10-27 |
| NCT05125016 | A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer | RECRUITING | PHASE1, PHASE2 | 2021-11-30 | 2027-01-14 | 2027-01-14 |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | TERMINATED | PHASE2 | 2021-11-30 | 2024-10-31 | 2024-10-31 |
| NCT04982224 | Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2021-11-09 | 2027-10-23 | 2027-08-22 |
| NCT05081388 | COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease | TERMINATED | PHASE1 | 2021-11-08 | 2022-06-30 | 2022-06-30 |
| NCT05102136 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers | COMPLETED | PHASE1 | 2021-10-27 | 2023-04-04 | 2023-04-04 |
| NCT05074433 | A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults | TERMINATED | PHASE3 | 2021-10-25 | 2022-05-18 | 2022-05-18 |
| NCT04577820 | Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP) | WITHDRAWN | PHASE3 | 2021-10-13 | 2022-10-08 | 2022-03-01 |
| NCT04992273 | COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age | TERMINATED | PHASE2 | 2021-09-13 | 2022-06-01 | 2022-06-01 |
| NCT04940364 | A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers | COMPLETED | PHASE1 | 2021-08-04 | 2022-06-22 | 2022-06-22 |
| NCT04981717 | A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat | TERMINATED | PHASE3 | 2021-07-30 | 2023-04-24 | 2023-01-04 |
| NCT04811716 | Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy | COMPLETED | PHASE2 | 2021-07-29 | 2023-10-18 | 2022-10-25 |
| NCT04863014 | Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis | TERMINATED | PHASE2 | 2021-07-12 | 2023-02-15 | 2023-02-15 |
| NCT04888507 | Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy | COMPLETED | PHASE2 | 2021-07-08 | 2023-05-04 | 2022-05-05 |
| NCT04646005 | Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy | COMPLETED | PHASE2 | 2021-06-28 | 2024-05-29 | 2023-05-22 |
| NCT04852978 | COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers | COMPLETED | PHASE2 | 2021-04-29 | 2022-11-21 | 2022-11-21 |
| NCT04417894 | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT) | COMPLETED | PHASE3 | 2021-04-14 | 2022-11-23 | 2022-08-31 |
| NCT04698187 | CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma | TERMINATED | PHASE2 | 2021-03-11 | 2024-02-05 | 2024-02-05 |
| NCT04695977 | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma | TERMINATED | PHASE2, PHASE3 | 2021-02-24 | 2024-07-22 | 2024-07-22 |
| NCT04633278 | CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | TERMINATED | PHASE2 | 2021-01-21 | 2024-01-19 | 2024-01-19 |
| NCT04709575 | Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis | COMPLETED | PHASE3 | 2021-01-14 | 2021-08-24 | 2021-08-24 |
| NCT04409080 | REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy | TERMINATED | PHASE1 | 2021-01-13 | 2024-10-17 | 2024-10-17 |
| NCT04626635 | A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | RECRUITING | PHASE1, PHASE2 | 2020-12-21 | 2026-12-12 | 2026-08-19 |
| NCT04666441 | COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection | COMPLETED | PHASE2 | 2020-12-15 | 2021-09-21 | 2021-03-04 |
| NCT04590326 | A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab | RECRUITING | PHASE1, PHASE2 | 2020-12-08 | 2027-11-30 | 2027-03-25 |
| NCT04616079 | Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volunteers | TERMINATED | PHASE1 | 2020-11-19 | 2021-06-01 | 2021-06-01 |
| NCT04616105 | Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult Volunteers | TERMINATED | PHASE1 | 2020-11-18 | 2021-05-28 | 2021-05-28 |
| NCT04601844 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers | COMPLETED | PHASE1 | 2020-11-16 | 2021-07-23 | 2021-07-23 |
| NCT04373083 | Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma | WITHDRAWN | PHASE2 | 2020-11-15 | 2025-02-20 | 2022-12-20 |
| NCT04614571 | T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge | COMPLETED | NA | 2020-11-02 | 2024-05-30 | 2024-05-30 |
| NCT04206553 | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid | COMPLETED | PHASE2, PHASE3 | 2020-10-28 | 2025-01-05 | 2024-07-12 |
| NCT04465487 | Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies | TERMINATED | PHASE1 | 2020-10-05 | 2025-02-07 | 2025-02-07 |
| NCT04442269 | Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED) | COMPLETED | PHASE2 | 2020-09-15 | 2024-02-09 | 2023-07-27 |
| NCT04394351 | Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE) | COMPLETED | PHASE3 | 2020-09-01 | 2024-05-14 | 2022-06-02 |
| NCT04506645 | Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans | COMPLETED | PHASE1 | 2020-09-01 | 2022-12-14 | 2022-12-14 |
| NCT04491838 | Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants | COMPLETED | PHASE1 | 2020-08-03 | 2021-03-05 | 2021-03-05 |
| NCT04519437 | Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19 | COMPLETED | PHASE1 | 2020-07-26 | 2021-11-22 | 2021-11-22 |
| NCT04203797 | A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma | COMPLETED | PHASE4 | 2020-07-16 | 2023-07-15 | 2023-07-15 |
| NCT04452318 | COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay | COMPLETED | PHASE3 | 2020-07-13 | 2021-10-04 | 2021-10-04 |
| NCT04429503 | Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease | COMPLETED | PHASE2, PHASE3 | 2020-06-29 | 2024-06-18 | 2022-05-30 |
| NCT04233918 | Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia | COMPLETED | PHASE3 | 2020-06-29 | 2023-05-30 | 2022-01-31 |
| NCT04425629 | Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19 | TERMINATED | PHASE3 | 2020-06-16 | 2022-06-09 | 2022-01-21 |
| NCT04426695 | Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19 | COMPLETED | PHASE1, PHASE2 | 2020-06-10 | 2021-10-22 | 2021-05-07 |
| NCT04315298 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | COMPLETED | PHASE2, PHASE3 | 2020-03-18 | 2020-09-02 | 2020-07-24 |
| NCT04154943 | Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | PHASE2 | 2020-03-10 | 2025-11-28 | 2021-12-01 |
| NCT04209634 | Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease) | COMPLETED | PHASE2, PHASE3 | 2020-01-27 | 2024-05-02 | 2021-11-09 |
| NCT04077099 | A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2020-01-07 | 2032-03-09 | 2032-03-09 |
| NCT04159415 | Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy | COMPLETED | PHASE2 | 2020-01-07 | 2024-09-24 | 2022-01-05 |
| NCT04162470 | REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability. | TERMINATED | PHASE3 | 2019-12-03 | 2022-04-07 | 2022-04-07 |
| NCT03888105 | A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies | RECRUITING | PHASE2 | 2019-11-13 | 2029-12-21 | 2028-08-28 |
| NCT04126317 | Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | COMPLETED | PHASE2 | 2019-11-04 | 2021-11-30 | 2021-05-14 |
| NCT04101721 | Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity | COMPLETED | PHASE3 | 2019-10-30 | 2022-08-18 | 2022-08-18 |
| NCT04083534 | First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) | COMPLETED | PHASE1, PHASE2 | 2019-09-26 | 2025-05-01 | 2025-05-01 |
| NCT03746704 | Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies | TERMINATED | PHASE1 | 2019-09-04 | 2021-07-08 | 2021-07-08 |
| NCT03972657 | A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors | RECRUITING | PHASE1, PHASE2 | 2019-08-12 | 2026-07-03 | 2025-08-01 |
| NCT03916627 | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | ACTIVE_NOT_RECRUITING | PHASE2 | 2019-07-23 | 2030-05-14 | 2025-03-31 |
| NCT03969004 | Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-06-04 | 2028-03-26 | 2026-11-03 |
| NCT03969849 | Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants | COMPLETED | PHASE1 | 2019-06-03 | 2020-03-27 | 2020-03-27 |
| NCT03956550 | A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee | TERMINATED | PHASE2 | 2019-05-21 | 2020-10-29 | 2020-05-01 |
| NCT03946748 | Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | COMPLETED | PHASE2 | 2019-05-16 | 2021-06-10 | 2021-06-09 |
| NCT03889912 | Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-04-11 | 2026-02-02 | 2025-11-22 |
| NCT03949673 | Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip | TERMINATED | PHASE2 | 2019-04-08 | 2020-08-25 | 2020-08-25 |
| NCT03793608 | Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy | COMPLETED | PHASE2 | 2019-03-12 | 2021-05-12 | 2021-02-19 |
| NCT03710941 | Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis | WITHDRAWN | PHASE2 | 2019-02-19 | 2020-11-05 | 2020-08-27 |
| NCT03838731 | Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge | COMPLETED | PHASE2 | 2019-02-12 | 2020-04-06 | 2019-12-21 |
| NCT03761108 | Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | RECRUITING | PHASE1, PHASE2 | 2019-01-23 | 2033-06-16 | 2033-03-30 |
| NCT03491904 | To Assess the Patients' Ability to Self-Administer Fasinumab | COMPLETED | PHASE1 | 2019-01-23 | 2020-12-15 | 2020-01-15 |
| NCT03767738 | Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe | COMPLETED | PHASE4 | 2018-12-19 | 2020-08-19 | 2020-08-19 |
| NCT03738423 | Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | TERMINATED | PHASE2 | 2018-11-13 | 2020-07-24 | 2020-03-13 |
| NCT03736967 | Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | TERMINATED | PHASE2 | 2018-11-12 | 2020-07-28 | 2020-03-13 |
| NCT03691974 | Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee | COMPLETED | PHASE2 | 2018-10-15 | 2021-01-07 | 2020-01-30 |
| NCT03682770 | Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) | COMPLETED | PHASE2 | 2018-10-03 | 2021-07-23 | 2020-10-16 |
| NCT03694197 | Long Term Safety Study of PRALUENT | TERMINATED | PHASE4 | 2018-09-28 | 2020-04-08 | 2020-04-08 |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | TERMINATED | PHASE1, PHASE2 | 2018-09-24 | 2023-05-10 | 2023-05-10 |
| NCT03633617 | Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) | COMPLETED | PHASE3 | 2018-09-24 | 2022-06-07 | 2021-09-09 |
| NCT03645746 | Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers | COMPLETED | PHASE1 | 2018-08-23 | 2019-09-30 | 2019-09-30 |
| NCT03515629 | REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer | TERMINATED | PHASE3 | 2018-07-02 | 2021-07-29 | 2021-07-29 |
| NCT03580694 | Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | TERMINATED | PHASE1 | 2018-06-27 | 2019-12-04 | 2019-12-04 |
| NCT03452228 | Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis | COMPLETED | PHASE2 | 2018-06-07 | 2020-07-23 | 2019-12-17 |
| NCT03558997 | Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy | COMPLETED | PHASE2 | 2018-06-07 | 2019-06-13 | 2019-05-14 |
| NCT03430063 | A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer | TERMINATED | PHASE2 | 2018-05-29 | 2021-10-27 | 2021-10-27 |
| NCT03564340 | Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | RECRUITING | PHASE1, PHASE2 | 2018-05-21 | 2027-01-31 | 2026-02-01 |
| NCT03530514 | A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers | COMPLETED | PHASE1 | 2018-04-24 | 2020-01-27 | 2020-01-27 |
| NCT03438318 | Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer | COMPLETED | PHASE1 | 2018-03-15 | 2019-12-11 | 2019-12-11 |
| NCT03409744 | Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia | COMPLETED | PHASE3 | 2018-03-13 | 2023-04-13 | 2023-04-13 |
| NCT03409614 | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | COMPLETED | PHASE3 | 2018-03-06 | 2025-02-27 | 2025-02-27 |
| NCT03188666 | A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva | COMPLETED | PHASE2 | 2018-02-26 | 2021-09-16 | 2019-09-16 |
| NCT03399786 | Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia | COMPLETED | PHASE3 | 2018-01-18 | 2020-03-17 | 2019-06-10 |
| NCT03346434 | Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL) | COMPLETED | PHASE2, PHASE3 | 2017-11-30 | 2021-07-08 | 2021-07-08 |
| NCT03345914 | Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) | COMPLETED | PHASE3 | 2017-11-17 | 2019-09-10 | 2019-06-20 |
| NCT03175367 | Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia | COMPLETED | PHASE2 | 2017-11-10 | 2020-12-14 | 2020-05-22 |
| NCT03285646 | Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee | TERMINATED | PHASE3 | 2017-10-30 | 2019-05-02 | 2018-05-05 |
| NCT03304379 | Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip | COMPLETED | PHASE3 | 2017-10-26 | 2020-11-09 | 2019-12-13 |
| NCT03156621 | Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | COMPLETED | PHASE3 | 2017-10-03 | 2020-02-13 | 2019-09-27 |
| NCT03257267 | Study of Cemiplimab in Adults With Cervical Cancer | COMPLETED | PHASE3 | 2017-09-05 | 2023-04-20 | 2021-03-15 |
| NCT03161093 | A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip | COMPLETED | PHASE3 | 2017-08-17 | 2021-08-27 | 2019-09-09 |
| NCT03198130 | An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1) | COMPLETED | PHASE1 | 2017-07-03 | 2020-02-21 | 2019-06-27 |
| NCT03132636 | PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy | COMPLETED | PHASE2 | 2017-06-29 | 2023-04-27 | 2021-05-20 |
| NCT03233139 | Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies | ACTIVE_NOT_RECRUITING | PHASE1 | 2017-06-21 | 2027-09-30 | 2027-09-30 |
| NCT03112577 | Study of REGN3500 and Dupilumab in Patients With Asthma | COMPLETED | PHASE1 | 2017-06-15 | 2019-12-09 | 2019-03-20 |
| NCT03088540 | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | COMPLETED | PHASE3 | 2017-05-29 | 2025-04-18 | 2025-04-18 |
| NCT03146416 | Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers | COMPLETED | PHASE1 | 2017-05-16 | 2018-06-14 | 2018-06-14 |
| NCT03115996 | Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers | COMPLETED | PHASE1 | 2017-05-10 | 2018-08-31 | 2018-08-31 |
| NCT03084640 | Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma | COMPLETED | PHASE1 | 2017-05-04 | 2021-09-30 | 2021-07-02 |
| NCT03002376 | An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1) | COMPLETED | PHASE1 | 2017-04-10 | 2020-03-19 | 2019-03-05 |
| NCT03054428 | Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis | COMPLETED | PHASE3 | 2017-03-21 | 2018-06-05 | 2018-04-04 |
| NCT03050151 | Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis | COMPLETED | PHASE1 | 2017-02-28 | 2018-02-12 | 2017-11-14 |
| NCT02999711 | Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma | COMPLETED | PHASE1 | 2017-02-03 | 2018-09-10 | 2018-08-30 |
| NCT02943239 | Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men | COMPLETED | PHASE1 | 2016-12-08 | 2019-04-30 | 2019-04-30 |
| NCT03005782 | Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers | COMPLETED | PHASE1 | 2016-11-07 | 2024-04-02 | 2024-04-02 |
| NCT02957682 | Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo | COMPLETED | PHASE4 | 2016-11-02 | 2020-03-05 | 2020-03-05 |
| NCT02958436 | A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects | COMPLETED | PHASE1 | 2016-08 | 2017-10-03 | 2017-06-18 |
| NCT02870400 | A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477 | COMPLETED | PHASE1 | 2016-07 | 2017-01-12 | 2017-01-12 |
| NCT02777151 | Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers | COMPLETED | PHASE1 | 2016-05-27 | 2017-04-26 | 2017-04-26 |
| NCT02680184 | Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy | COMPLETED | PHASE1 | 2016-04-12 | 2022-12-06 | 2022-12-06 |
| NCT02760498 | Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | COMPLETED | PHASE2 | 2016-04-07 | 2023-10-18 | 2023-10-18 |
| NCT02828397 | Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects | COMPLETED | PHASE1 | 2016-04 | 2016-09 | 2016-09 |
| NCT02713204 | Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection | COMPLETED | PHASE2 | 2016-03-31 | 2017-10-03 | 2017-10-03 |
| NCT02718326 | Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) | COMPLETED | PHASE3 | 2016-03-29 | 2019-07-16 | 2018-08-06 |
| NCT02712008 | Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema | COMPLETED | PHASE2 | 2016-03-02 | 2017-07-10 | 2017-07-10 |
| NCT02741739 | Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects | COMPLETED | PHASE1 | 2016-03 | 2016-05 | 2016-04 |
| NCT02683239 | Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip | COMPLETED | PHASE3 | 2016-02-17 | 2021-06-15 | 2020-12-01 |
| NCT02755649 | A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable | COMPLETED | PHASE3 | 2016-01-31 | 2017-03-31 | 2017-01-04 |
| NCT02620020 | A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain | COMPLETED | PHASE2, PHASE3 | 2016-01-26 | 2017-09-13 | 2017-02-03 |
| NCT02651662 | A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies | ACTIVE_NOT_RECRUITING | PHASE1 | 2016-01-11 | 2025-12-27 | 2025-12-27 |
| NCT02647086 | Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) | COMPLETED | PHASE1 | 2015-12 | 2016-07 | 2016-07 |
| NCT02612454 | Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) | ACTIVE_NOT_RECRUITING | PHASE3 | 2015-10-15 | 2026-10-07 | 2026-10-07 |
| NCT02520245 | Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study | WITHDRAWN | PHASE1 | 2015-08 | 2023-11 | 2023-11 |
| NCT02325791 | Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants | COMPLETED | PHASE3 | 2015-07-21 | 2017-09-26 | 2017-07-05 |
| NCT02516618 | Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects | COMPLETED | PHASE1 | 2015-07 | 2016-02 | 2016-02 |
| NCT02379052 | Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE) | COMPLETED | PHASE2 | 2015-05-12 | 2017-07-10 | 2017-02-17 |
| NCT02418754 | Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) | TERMINATED | PHASE2 | 2015-05-05 | 2017-04-03 | 2016-08-17 |
| NCT02447276 | Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip | COMPLETED | PHASE2, PHASE3 | 2015-05 | 2016-11 | 2016-03 |
| NCT02407756 | A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema) | COMPLETED | PHASE2 | 2015-03-31 | 2016-03-31 | 2016-03-31 |
| NCT02326220 | Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy | COMPLETED | PHASE3 | 2015-03-31 | 2016-04-30 | 2016-01-31 |
| NCT02395133 | A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD) | COMPLETED | PHASE3 | 2015-03-25 | 2016-10-18 | 2016-07 |
| NCT02265952 | Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | COMPLETED | PHASE2 | 2015-02-04 | 2018-07-23 | 2016-11-21 |
| NCT02383212 | Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies | COMPLETED | PHASE1 | 2015-02-02 | 2019-11-18 | 2019-11-18 |
| NCT02290951 | Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies | COMPLETED | PHASE1 | 2015-01-09 | 2025-08-21 | 2025-08-21 |
| NCT02277769 | Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | COMPLETED | PHASE3 | 2014-11-30 | 2016-01-31 | 2015-10-31 |
| NCT01997164 | Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME) | COMPLETED | PHASE1 | 2014-11 | 2015-10 | 2015-10 |
| NCT02127801 | Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants | COMPLETED | PHASE1 | 2014-10-31 | 2015-12-31 | 2015-12-31 |
| NCT02277743 | Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | COMPLETED | PHASE3 | 2014-10 | 2016-02 | 2015-11 |
| NCT02284425 | Study of REGN1193 in Patients With Type 2 Diabetes Mellitus | TERMINATED | PHASE1 | 2014-10 | 2015-12 | 2015-12 |
| NCT02260986 | Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis | COMPLETED | PHASE3 | 2014-09 | 2016-10 | 2015-08 |
| NCT02210780 | Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD) | COMPLETED | PHASE2 | 2014-08-05 | 2015-09-15 | 2015-09-15 |
| NCT02121080 | Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers | COMPLETED | PHASE1 | 2014-05 | 2015-02 | 2015-02 |
| NCT02107872 | Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500 | COMPLETED | PHASE1 | 2014-04 | 2015-09 | 2015-09 |
| NCT02097524 | Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA) | COMPLETED | PHASE1 | 2014-03 | 2015-04 | 2015-04 |
| NCT02061865 | Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD | COMPLETED | PHASE1 | 2014-02 | 2014-12 | 2014-12 |
| NCT01979016 | Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD) | COMPLETED | PHASE2 | 2013-12-31 | 2015-01-31 | 2014-12-31 |
| NCT01963598 | Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia | COMPLETED | PHASE2 | 2013-11 | 2015-02 | 2015-01 |
| NCT01949311 | Open-label Study of Dupilumab in Patients With Atopic Dermatitis | COMPLETED | PHASE3 | 2013-10-10 | 2022-06-27 | 2022-06-27 |
| NCT01926782 | Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1) | COMPLETED | PHASE3 | 2013-09 | 2015-04 | 2014-09 |
| NCT01933763 | An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193 | COMPLETED | PHASE1 | 2013-08 | 2015-01 | 2015-01 |
| NCT01910220 | Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786) | COMPLETED | PHASE1 | 2013-08 | 2014-10 | 2014-06 |
| NCT01922661 | Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects | COMPLETED | PHASE1 | 2013-08 | 2014-05 | 2014-05 |
| NCT01893528 | Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers | COMPLETED | PHASE1 | 2013-06 | 2014-09 | 2014-09 |
| NCT01859988 | Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | COMPLETED | PHASE2 | 2013-05 | 2014-09 | 2014-05 |
| NCT01749878 | Study to Assess the Safety and Tolerability of Single Doses of REGN1500 | COMPLETED | PHASE1 | 2012-12 | 2016-01 | 2016-01 |
| NCT01709500 | Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) | COMPLETED | PHASE3 | 2012-12 | 2015-01 | 2014-05 |
| NCT01730053 | Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II) | COMPLETED | PHASE3 | 2012-11-30 | 2014-05-31 | 2014-04-30 |
| NCT01722045 | Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) | COMPLETED | PHASE4 | 2012-11 | 2015-09 | 2015-09 |
| NCT01730040 | Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I) | COMPLETED | PHASE3 | 2012-10 | 2014-05 | 2014-04 |
| NCT01727869 | Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer | COMPLETED | PHASE1 | 2012-10 | 2015-01 | 2015-01 |
| NCT01688960 | Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies | COMPLETED | PHASE1 | 2012-10 | 2014-11 | 2014-11 |
| NCT01720576 | Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786) | COMPLETED | PHASE1 | 2012-10 | 2013-06 | 2013-06 |
| NCT01709513 | Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE) | COMPLETED | PHASE3 | 2012-09-30 | 2017-05-31 | 2014-05-31 |
| NCT01639040 | Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD) | COMPLETED | PHASE2 | 2012-07 | 2012-12 | 2012-12 |
| NCT01605708 | Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis | TERMINATED | PHASE1, PHASE2 | 2012-06 | 2013-04 | 2013-04 |
| NCT01548404 | Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis | COMPLETED | PHASE2 | 2012-04 | 2013-06 | 2013-03 |
| NCT01521559 | Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO) | COMPLETED | PHASE3 | 2012-04 | 2014-03 | 2013-08 |
| NCT01540539 | Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy Volunteers | COMPLETED | PHASE1 | 2012-03 | 2013-01 | 2013-01 |
| NCT01576484 | Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) | COMPLETED | PHASE2 | 2012-02-28 | 2016-12-22 | 2016-12-22 |
| NCT01604824 | A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene | COMPLETED | PHASE2 | 2012-02-22 | 2017-07-28 | 2014-06-02 |
| NCT01507402 | A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786) | COMPLETED | PHASE1 | 2012-01 | 2012-11 | 2012-11 |
| NCT01484600 | Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers | COMPLETED | PHASE1 | 2011-12 | 2012-02 | 2012-02 |
| NCT01459796 | Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares | TERMINATED | PHASE3 | 2011-11 | 2013-06 | 2013-06 |
| NCT01451645 | Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol | COMPLETED | PHASE4 | 2011-10 | 2012-09 | 2012-08 |
| NCT01385657 | Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis | COMPLETED | PHASE1 | 2011-07-31 | 2012-03-31 | 2012-03-31 |
| NCT01363440 | Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema | COMPLETED | PHASE3 | 2011-05 | 2014-11 | 2013-01 |
| NCT01266876 | Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia | COMPLETED | PHASE2 | 2011-01 | 2011-11 | 2011-11 |
| NCT01271972 | Study of Nesvacumab (REGN910/ SAR307746) | COMPLETED | PHASE1 | 2011-01 | 2015-05 | 2014-09 |
| NCT01259323 | Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis | COMPLETED | PHASE1 | 2010-12 | 2012-07 | 2012-07 |
| NCT01209793 | Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers | COMPLETED | PHASE1 | 2010-11 | 2011-09 | 2011-09 |
| NCT01197391 | Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers | COMPLETED | PHASE1 | 2010-08 | 2012-03 | 2012-03 |
| NCT01161082 | Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin | COMPLETED | PHASE1 | 2010-06 | 2011-05 | 2011-05 |
| NCT01074372 | Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers | COMPLETED | PHASE1 | 2010-03 | 2010-11 | 2010-11 |
| NCT00964795 | Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD) | COMPLETED | PHASE3 | 2009-12 | 2013-08 | 2013-08 |
| NCT01001923 | Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain | TERMINATED | PHASE2 | 2009-12 | 2011-01 | 2011-01 |
| NCT01001715 | Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain | TERMINATED | PHASE2 | 2009-11 | 2011-01 | 2011-01 |
| NCT01026597 | Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers | COMPLETED | PHASE1 | 2009-11 | 2010-10 | 2010-10 |
| NCT00991172 | A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain | COMPLETED | PHASE2 | 2009-11 | 2010-05 | 2010-05 |
| NCT01015027 | Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers | COMPLETED | PHASE1 | 2009-10 | 2010-07 | 2010-07 |
| NCT00944892 | A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee | COMPLETED | PHASE1, PHASE2 | 2009-08 | 2010-05 | 2010-05 |
| NCT00958438 | PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2) | COMPLETED | PHASE3 | 2009-07 | 2010-12 | 2010-12 |
| NCT00943072 | Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) | COMPLETED | PHASE3 | 2009-07 | 2012-04 | 2010-10 |
| NCT00871559 | A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies | COMPLETED | PHASE1 | 2009-06 | 2014-02 | 2014-02 |
| NCT00855920 | Study Utilizing Rilonacept in Gout Exacerbations | COMPLETED | PHASE3 | 2009-03 | 2010-02 | 2010-02 |
| NCT00856206 | Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE) | COMPLETED | PHASE3 | 2009-03 | 2011-01 | 2011-01 |
| NCT00829829 | PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1 | COMPLETED | PHASE3 | 2009-02 | 2010-06 | 2010-05 |
| NCT00856310 | A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects | COMPLETED | PHASE1 | 2009-02 | 2009-11 | 2009-11 |
| NCT00789477 | DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact | COMPLETED | PHASE2 | 2008-12 | 2010-09 | 2009-12 |
| NCT01011959 | A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects | COMPLETED | PHASE1 | 2008-12 | 2009-08 | 2009-08 |
| NCT00794417 | A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma | TERMINATED | PHASE1, PHASE2 | 2008-11-30 | 2011-06-30 | 2011-06-30 |
| NCT01026519 | A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis | COMPLETED | PHASE1 | 2008-09 | 2009-05 | 2009-03 |
| NCT01055899 | Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis | COMPLETED | PHASE1 | 2008-07 | 2009-03 | 2009-03 |
| NCT00610363 | Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares | COMPLETED | PHASE2 | 2007-11 | 2008-10 | 2008-10 |
| NCT00527423 | Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD | COMPLETED | PHASE2 | 2007-08 | 2011-10 | 2011-10 |
| NCT00509795 | Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD) | COMPLETED | PHASE3 | 2007-08 | 2011-07 | 2010-09 |
| NCT00383370 | Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD | COMPLETED | PHASE1 | 2006-10 | 2008-07 | 2007-09 |
| NCT00320788 | Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD) | COMPLETED | PHASE2 | 2006-04 | 2008-08 | 2008-06 |
| NCT00320814 | Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema | COMPLETED | PHASE1 | 2006-04 | 2007-08 | 2006-08 |
| NCT00288704 | Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) | COMPLETED | PHASE3 | 2005-12 | 2008-08 | 2008-06 |
| NCT01803321 | Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA) | COMPLETED | PHASE1 | 2005-11 | 2008-06 | 2008-06 |
| NCT00320775 | Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD | COMPLETED | PHASE1 | 2005-06 | 2008-08 | 2008-06 |
| NCT00082823 | Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | COMPLETED | PHASE1 | 2004-01 | | 2008-05 |
| NCT00083213 | Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | COMPLETED | PHASE1 | 2004-01 | | 2008-05 |
| NCT00045266 | VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma | COMPLETED | PHASE1 | 2002-04 | | 2007-02 |
| NCT00036946 | VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma | COMPLETED | PHASE1 | 2001-11 | | 2002-03 |
| NCT01239017 | A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee | WITHDRAWN | PHASE2 | | | |
| NCT01053702 | Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury | WITHDRAWN | PHASE2 | | | |
| NCT00609544 | Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia | WITHDRAWN | PHASE2 | | | |